Reactivation of Maculopapular Drug Eruption Lesions Suspected to be Caused by Allopurinol During 72 Hours-Patch Test: a Case Report

  • Triasari Oktavriana Departemen Dermatologi dan Venereologi, Fakultas Kedokteran Universitas Sebelas Maret Surakarta, Indonesia
  • Irene Ardiani Pramudya Wardhani Department of Dermatology and Venereology Faculty of Medicine Sebelas Maret University Surakarta, Indonesia
Keywords: Teacher Emotional Labor, Teacher Work Engagement, Teacher Commitment, Teacher Performance


Maculopapular drug eruption is a delayed-type T-cell-mediated hypersensitivity reaction to a drug that is most commonly encountered within one week of suspected drug exposure. Allopurinol is a drug that is often found as a cause of drug allergic eruptions. The drug patch test can be used to identify the causative agent of a drug eruption. A 56-year-old man came with the chief complaint of itchy red patches on his face, chest, back, hands and feet for the past two weeks. The patches appeared five days after the patient took allopurinol for his hyperuricemia. The patient was diagnosed with maculopapular drug eruption with suspected to be caused by allopurinol. Six weeks after the patient was free from any lesions and eligible, a patch test was performed but the results were negative in all chambers on all reading days. At 72 hours after the patch test, there was reactivation of the skin lesions which obscured the patch test results. Maculopapular drug eruptions can be triggered by drug metabolites or drug absorption from the patch test itself is sufficient to cause reactivation.


Download data is not yet available.


Stern RS. Exanthematous Drug Eruptions. N Engl J Med. 2012; 366(2): 2492–501. Google Scholar

Heelan K, Sibbald C, Shear NH. Cutaneous Reactions to Drugs. Dalam: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, dkk., penyunting. Fitzpatrick’s dermatology. Edisi ke-9. New York: McGraw-Hill Education; 2019. h. 749–64.

Yawalkar Dr. N. Maculopapular drug eruptions. Karger. 2007; 2(2): 242–50. Google Scholar

Gaya ML, Akhyar G. Studi retrospektif erupsi obat alergik di RS dr. M. Djamil Padang periode Januari 2014 – Desember 2016. J Kesehat Andalas. 2018; 7(2): 51–3. Google Scholar

Mahajan VK, Handa S. Patch testing in cutaneous adverse drug reactions: Methodology, interpretation, and clinical relevance. Indian J Dermator Venereol Leprol. 2013; 79(8): 836–41. Google Scholar

Lazzarini R, Duarte I, Ferreira AL. Patch tests. An Bras Dermatol. 2012; 88(6): 879–88. Google Scholar

Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Elsevier. 2005; 209(12): 209–16. Google Scholar

Salman A, Yucelten D, Cakici OA, Kadayifci EK. Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test. Wiley Period. 2019; 36(5): 514–6. Google Scholar

Córdoba S, Navarro-Vidal B, Martínez-Morán C, Borbujo J. Reactivation of Skin Lesions After Patch Testing to Investigate Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome? Actas Dermosifiliogr. 2016; 107(9): 781–98. Google Scholar

Shalom R, Rimbroth S, Rozenman D, Markel A. Allopurinol-Induced Recurrent DRESS Syndrome: Pathophysiology and Treatment. Ren Fail. 2008; 30(3): 327–9. Google Scholar

Stern RS. Exanthematous Drug Eruptions. N Engl J Med. 2012; 366(26): 2492–501. Google Scholar

Wolff K, Johnson RA, Saavadra AP, Roh EK. Exanthematous Drug Reactions. In: Edmonson K, penyunting. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 8th ed. New York: McGraw-Hill Education; 2017. h. 494–5.

Yunihastuti E, Widhani A, Karjadi TH. Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. apallergy. 2014; 4(1): 55–67. Google Scholar

Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, dkk. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013; 168(5): 555–62. Google Scholar

Aquino MR, Sher J, Fonacier L. Patch Testing for Drugs. Dermatitis. 2013; 24(5): 205–14. Google Scholar

Wibisono Y, Damayanti. Skin Test for Cutaneous Adverse Drug Reactions. Berk Ilmu Kesehat Kulit Kelamin. 2020; 32(1): 62–9. Google Scholar

Teo YX, Ardern-Jones MR. Reactivation of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) with Ranitidine Patch Testing. Chem. 2007; 107(2): 2411–502. Google Scholar

Fatangarea A, Glassner A, Sachs B, Sickmanna A. Future perspectives on in-vitro diagnosis of drug allergy by the lymphocyte transformation test. J Immunol Methods. 2021; 495(11): 1–7. Google Scholar

Strazzula L, Pratt DS, Zardas J, Chung RT, Thiim M, Kroshinsky D. Widespread Morbilliform Eruption Associated With Telaprevir Use of Dermatologic Consultation to Increase Tolerability. JAMA Dermatol. 2014; 150(7): 756–9. Google Scholar

Wolf K, Johnson RA, Saavedra AP, Roh EK. Adverse Cutaneous Drug Reactions. In: Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. Edisi ke-8. New York; 2017. h. 489–512.

Hoetzenecker W, Nägeli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, dkk. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2015; 281(15): 540–12. Google Scholar

Caplan A, Fett N, Werth V. Glucocorticoids. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, dkk., penyunting. Fitzpatrick’s dermatology. Edisi ke-9. New York: McGraw-Hill Education; 2019. h. 3382-94. Google Scholar